• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DINACICLIB Drug Record

  • Summary
  • Interactions
  • Claims
  • DINACICLIB chembl:CHEMBL2103840 Antineoplastic

    Alternate Names:

    MK-7965
    DINACICLIB
    SCH-727965

    Drug Info:

    Pharmaceutical Developer Merck
    Source Reported Drug Name(s) Dinaciclib (SCH727965)
    Drug Class Pan-CDK Inhibitor
    Drug Class Kinase Inhibitors
    (6 More Sources)

    Publications:

    Chen Z et al., 2016, Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity., Sci Rep
    Schonbrunn E et al., 2013, Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases., J Med Chem
    Au-Yeung et al., 2017, Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition., Clin. Cancer Res.
    Danilov et al., 2016, Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2., Mol. Cancer Ther.
    Hu et al., 2015, Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models., Mol. Cancer Ther.
    Baker et al., 2016, The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia., Cancer Res.
  • DINACICLIB   CCNE1

    Interaction Score: 4.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27663592


    Sources:
    ClearityFoundationBiomarkers CIViC

  • DINACICLIB   CDK9

    Interaction Score: 1.87

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Direct Interaction yes
    Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor

    PMIDs:
    27378523


    Sources:
    MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CIViC CancerCommons

  • DINACICLIB   CDK2

    Interaction Score: 0.79

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Mechanism of Interaction Cyclin-dependent kinase 2 inhibitor
    Direct Interaction yes

    PMIDs:
    23600925


    Sources:
    DTC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

  • DINACICLIB   CDK1

    Interaction Score: 0.72

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

  • DINACICLIB   CDK5

    Interaction Score: 0.65

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 5 inhibitor
    Direct Interaction yes
    Reported Cancer Type Melanoma

    PMIDs:
    None found


    Sources:
    MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons

  • DINACICLIB   NRAS

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type acute myeloid leukemia
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26627013


    Sources:
    JAX-CKB

  • DINACICLIB   KMT2A

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type acute myeloid leukemia
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26627013


    Sources:
    JAX-CKB

  • DINACICLIB   MYC

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • DINACICLIB   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dinaciclib + MK2206
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    27550941 25931518


    Sources:
    JAX-CKB

  • MyCancerGenome: DINACICLIB

    • Version: 20-Jun-2017

    Alternate Names:
    SCH727965 Development Name
    DINACICLIB Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • CancerCommons: SCH727965

    • Version: 25-July-2013

    Alternate Names:
    Dinaciclib PubChem Drug Name
    46926350 PubChem Drug ID
    Dinaciclib Drug Trade Name

    Drug Info:
    Drug Class Pan-CDK Inhibitor
    Source Reported Drug Name(s) Dinaciclib (SCH727965)
    Pharmaceutical Developer Merck

    Publications:

  • DTC: DINACICLIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL2103840 ChEMBL Drug ID

    Drug Info:

    Publications:
    Schonbrunn E et al., 2013, Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases., J Med Chem

  • JAX-CKB: Dinaciclib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Baker et al., 2016, The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia., Cancer Res.
    Danilov et al., 2016, Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2., Mol. Cancer Ther.
    Hu et al., 2015, Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models., Mol. Cancer Ther.

  • CIViC: DINACICLIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Au-Yeung et al., 2017, Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition., Clin. Cancer Res.
    Chen Z et al., 2016, Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity., Sci Rep

  • ChemblDrugs: chembl:CHEMBL2103840

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: DINACICLIB

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: DINACICLIB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL2103840

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: DINACICLIB

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21